| 产品名称： | Streptococcus equi subsp. zooepidemicus Farrow and Collins |
|---|---|
| 商品货号： | TS215241 |
| Strain Designations： | HA-116 |
| Application： | Patented for production of high molecular weight hyaluronic acid. ATCC does not confirm or test for the production of hyaluronic acid. |
| Isolation： | Nitrosoguanidine-induced mutant of clinical isolate HA-100 |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Storage Conditions： | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Preceptrol®： | no |
| Type Strain： | no |
| Medium： | ATCC® Medium 44: Brain Heart Infusion Agar/Broth ATCC® Medium 260: Trypticase soy agar/broth with defibrinated sheep blood |
| Growth Conditions： | Temperature: 37°C
Atmosphere: Aerobic |
| Name of Depositor： | Biotechnology General Corp. |
| U.S. Patent Number： | |
| References： | Nimrod A, et al. Method of producing high molecular weight sodium hyallronate by fermentation of Streptococcus. US Patent 4,780,414 dated Oct 25 1988 Nimrod A, et al. High molecular weight sodium hyaluronate. US Patent 4,784,990 dated Nov 15 1988 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Streptococcus equi subsp. zooepidemicus Farrow and Collins |
|---|---|
| 商品货号： | TS215241 |
| Strain Designations： | HA-116 |
| Application： | Patented for production of high molecular weight hyaluronic acid. ATCC does not confirm or test for the production of hyaluronic acid. |
| Isolation： | Nitrosoguanidine-induced mutant of clinical isolate HA-100 |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Storage Conditions： | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Preceptrol®： | no |
| Type Strain： | no |
| Medium： | ATCC® Medium 44: Brain Heart Infusion Agar/Broth ATCC® Medium 260: Trypticase soy agar/broth with defibrinated sheep blood |
| Growth Conditions： | Temperature: 37°C
Atmosphere: Aerobic |
| Name of Depositor： | Biotechnology General Corp. |
| U.S. Patent Number： | |
| References： | Nimrod A, et al. Method of producing high molecular weight sodium hyallronate by fermentation of Streptococcus. US Patent 4,780,414 dated Oct 25 1988 Nimrod A, et al. High molecular weight sodium hyaluronate. US Patent 4,784,990 dated Nov 15 1988 |
